Citron believes that the North Carolina-based company could double from its opening position Monday, as long as investors are still pot crazy.
$PYX would not short...speculative long. Real management and tight float. The stock could double from here as long as investors are Cannabis crazy. Our favorite hire..and it wasn't last week. https://t.co/mPdfuGBVJe— Citron Research (@CitronResearch) October 8, 2018
Pyxus supplies tobacco leaves to cigarette manufacturers, but, since it announced on October 2 that its indirect subsidiary Goldleaf Pharm received a medical cannabis cultivation license in Canada the company has been swept up in the cannabis craze.
Shares of Pyxus closed trading up 36.6% to $38.52 Monday.